VCYT Q1 2023 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$82M+21.6% YoY

Gross Profit

$56M68.2% margin

Operating Income

-$10M-12.7% margin

Net Income

-$8M-9.8% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

+2.6%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$3M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$76M

Stockholders' Equity

$1.1B

Cash & Equivalents

$178M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$82M	$68M	+21.6%
Gross Profit	$56M	$44M	+27.5%
Operating Income	-$10M	-$15M	+31.2%
Net Income	-$8M	-$14M	+44.0%

Revenue Segments

Testing

$72M88%

Biopharmaceutical And Other

$6M7%

Product

$4M5%